Medication leaflets

Active substance

Results for the substance avatrombopag

3 results

About this active substance

Avatrombopag is a thrombopoietin receptor agonist used in the treatment of thrombocytopenia in patients with chronic liver disease who are scheduled to undergo invasive procedures. It stimulates platelet production by activating the thrombopoietin receptor on the surface of megakaryocytes and their precursors.

Avatrombopag is administered orally, usually once daily, for several days prior to the planned procedure. It is indicated for patients with severe thrombocytopenia to reduce the risk of bleeding associated with medical interventions.

Common side effects include headache, nausea, fatigue, and peripheral edema. In rare cases, severe adverse reactions such as deep vein thrombosis or thromboembolic events may occur. Regular monitoring of platelet counts and other hematological parameters is essential during treatment.

Avatrombopag is an effective and well-tolerated therapeutic option for managing thrombocytopenia, contributing to reduced bleeding risk and improved safety of medical procedures.